The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$18.14

Today's change+0.38 +2.14%
Updated August 22 3:18 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$18.14

Today's change+0.38 +2.14%
Updated August 22 3:18 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc up sharply

Valeant Pharmaceuticals International Inc is up sharply today, rallying $0.38 or 2.14% to $18.14. Over the last five days, shares have gained 2.14%, but are down 6.83% for the last year to date. Shares have underperformed the S&P TSX by 56.96% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward4.66×
  • Forward PEG0.63×
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$4.12
Updated August 22 3:18 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-12.35%

Although this company's net profit margin is negative, it is above the industry average and implies that Valeant Pharmaceuticals International Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.31%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue2,2332,1092,4032,480
Total other revenue--------
Total revenue2,2332,1092,4032,480
Gross profit1,5871,5131,7371,822
Total cost of revenue646596665658
Total operating expense2,0581,9622,2523,343
Selling / general / administrative659661665661
Research & development949693101
Depreciation / amortization623635284807
Interest expense (income), net operating--------
Unusual expense (income)38-274531,115
Other operating expenses, total-21931
Operating income175147150-863
Interest income (expense), net non-operating-459-474-467-470
Gain (loss) on sale of assets--------
Other--------
Income before tax-242-295-360-1,332
Income after tax-37629-512-1,219
Income tax, total-205-924152-113
Net income-38628-515-1,218
Total adjustments to net income--------
Net income before extra. items-38628-515-1,218
Minority interest-1-1-31
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-38628-515-1,218
Inc. avail. to common incl. extra. items-38628-515-1,218
Diluted net income-38627-515-1,218
Dilution adjustment---1----
Diluted weighted average shares350351350350
Diluted EPS excluding extraordinary itemsvalue per share-0.111.79-1.47-3.49
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.041.77-0.65-1.38